Supplemental Figure 1 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Authors:

Abstract
The generation of the screening ADA signal and confirmatory inhibition by the affinity-capture elution-bridge assay format.